Investigational drug · Phase 3
ADSTEM Inj.
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Atopic Dermatitis.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
5
Any phase or sponsor naming "ADSTEM Inj."
First trial start
2019
Dec 11, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ADSTEM Inj.", any sponsor or status.
Conditions studied
As listed on its trial records.
- Atopic Dermatitis
Approved drugs for the same conditions: Atopic dermatitis (eczema) · Immunology and inflammation · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "ADSTEM Inj." as an intervention, largest first.
- Study of ADSTEM Injection for Patients With Moderate to Severe Subacute and Chronic Atopic DermatitisPivotal-lookingRecruiting
EHL Bio Co., Ltd.Industry
NCT07377838 · 286 participants (planned) · Start Sep 15, 2026 · Primary completion Sep 2029
Drug: ADSTEM Inj.; Placebo · For: Atopic Dermatitis
Sites: Cheonan, South Korea
- Orthobiologic Treatment for Knee OsteoarthritisPivotal-lookingEnrolling by invitation
University Hospital of North NorwayAcademic, hospital or other
NCT06893250 · 160 participants (planned) · Start Sep 23, 2024 · Primary completion Dec 2027
Drug: PRP injection; ADSTEM Inj. (Adult human mesenchymal stem cells) and 2 more · For: Osteoarthritis Knee
Sites: Tromsø, Norway
- Safety and Efficacy in Patients With Moderate to Severe Subacute and Chronic Atopic DermatitisPivotal-lookingActive, not recruiting
EHL Bio Co., Ltd.Industry
NCT04137562 · 118 participants · Start Dec 11, 2019 · Primary completion Jan 26, 2023
Drug: ADSTEM Inj. · For: Atopic Dermatitis
Sites: Daejeon, South Korea; Ansan, South Korea; Seoul, South Korea · 6 sites in all
EHL Bio Co., Ltd.Industry
NCT02888704 · 13 participants · Start Jul 2016 · Primary completion Dec 2017
Drug: ADSTEM Inj. (Adult human mesenchymal stem cells) · For: Atopic Dermatitis
Sites: Daejeon, South Korea
EHL Bio Co., Ltd.Industry
NCT03252340 · 11 participants · Start Sep 19, 2017 · Primary completion Aug 17, 2022
Drug: ADSTEM Inj. · For: Atopic Dermatitis
Sites: Daejeon, South Korea
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Atopic Dermatitis
- AfimkibartRO7790121, RVT-3101Phase 312 trials
Roche (Genentech) · Moderately to Severely Active Ulcerative Colitis, Moderately to Severely Active Crohns Disease, Atopic Dermatitis
- CM512Phase 39 trials
Keymed Biosciences Co.Ltd · Chronic Rhinosinusitis With Nasal Polyposis, Chronic Spontaneous Urticaria (CSU), Asthma
- LutikizumabABT-981Phase 38 trials
AbbVie · Hidradenitis Suppurativa, Atopic Dermatitis, Rheumatoid Arthritis
- PF-07275315tilrekimigPhase 38 trials
Pfizer · Atopic Dermatitis, Asthma, Moderate to Severe Chronic Obstructive Pulmonary Disease
- barzolvolimabCDX-0159Phase 37 trials
Celldex Therapeutics · Chronic Spontaneous Urticaria, Chronic Inducible Urticaria, Cold Urticaria
- MG-K10Humanized Monoclonal AntibodyPhase 36 trials
Shanghai Mabgeek Biotech.Co.Ltd · Dermatitis, Atopic, Chronic Urticaria, Idiopathic, Atopic Dermatitis
- CM310Phase 35 trials
Keymed Biosciences Co.Ltd · Atopic Dermatitis, Moderate to Severe Asthma, Chronic Obstructive Pulmonary Disease
- VC005Phase 35 trials
Jiangsu vcare pharmaceutical technology co., LTD · Non-segmental Vitiligo, Non-Segmental Vitiligo, Atopic Dermatitis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.